Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Treatment Modification
100%
Antidiabetic Drugs
100%
Sulfonylurea
60%
High Risk
40%
Medication Use
40%
A1 Receptor
40%
Receptor Agonist
40%
Medication Classes
40%
Dipeptidyl peptidase-4 (DPP-4)
40%
Glucagon-like
40%
Health Systems
20%
Medication Prescription
20%
Family Medicine
20%
Endocrinologist
20%
Female Sex
20%
Medication Adherence
20%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
20%
Second-line Therapy
20%
Patient Support
20%
Retrospective Cohort Study
20%
Glucagon-like peptide-1 (GLP-1)
20%
Low Risk
20%
12-month Follow-up
20%
Adjusted Analysis
20%
Thiazolidinediones
20%
Group Sex
20%
Young Subgroup
20%
Internal Medicine Physicians
20%
Private Health Plan
20%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Sulfonylurea
100%
Glucagon-Like Peptide-1 Agonist
66%
Dipeptidyl Peptidase-4 Inhibitor
66%
Retrospective Cohort Study
33%
Endocrinologist
33%
Medication Compliance
33%
Glucagon Like Peptide 1
33%
Thiazolidinedione
33%
Sodium Glucose Cotransporter 2 Inhibitor
33%
Prescription Medication
33%
Family Practice
33%
Internal Medicine
33%
Health System
33%
Pharmacology, Toxicology and Pharmaceutical Science
Sulfonylurea
100%
Non Insulin Dependent Diabetes Mellitus
100%
Glucagon Like Peptide 1 Receptor Agonist
66%
Dipeptidyl Peptidase IV Inhibitor
66%
Cohort Study
33%
Prescription Medication
33%
Sodium Glucose Cotransporter 2 Inhibitor
33%
Glucagon-Like Peptide-1
33%
Thiazolidinedione
33%